AKTS Overview

Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.

Wall Street analysts forecast AKTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is31.67 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aktis Oncology Inc revenue for the last quarter amounts to 9.03M USD, increased 28.92

Aktis Oncology Inc. EPS for the last quarter amounts to -0.04 USD, decreased -85.71

Aktis Oncology Inc (AKTS) has 117 emplpoyees as of February 19 2026.

Today AKTS has the market capitalization of 925.97M USD.